Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Preparation of Cell Cultures and Vaccinia Virus Stocks.

Literature DB >> 26528781

Preparation of Cell Cultures and Vaccinia Virus Stocks.

Catherine A Cotter¹, Patricia L Earl¹, Linda S Wyatt¹, Bernard Moss¹.

Abstract

The culturing of cell lines used with vaccinia virus, both as monolayer and in suspension, is described. The preparation of chick embryo fibroblasts (CEF) is presented for use in the production of the highly attenuated and host range-restricted modified vaccinia virus Ankara (MVA) strain of vaccinia virus. Protocols for the preparation, titration, and trypsinization of vaccinia virus stocks, as well as viral DNA preparation and virus purification methods are also included.

Entities: CellLine Chemical Disease Gene Species

Keywords: cell culture; modified vaccinia virus Ankara; vaccinia virus

Mesh：

Substances：
DNA, Viral

Year: 2015 PMID： 26528781 PMCID： PMC5081219 DOI： 10.1002/9780471729259.mc14a03s39

Source DB: PubMed Journal: Curr Protoc Microbiol

5 in total

1. Mapping of deletions in the genome of the highly attenuated vaccinia virus MVA and their influence on virulence.

Authors: H Meyer; G Sutter; A Mayr
Journal: J Gen Virol Date: 1991-05 Impact factor: 3.891

2. Gene expression using the vaccinia virus/T7 RNA polymerase hybrid system.

Authors: O Elroy-Stein; B Moss
Journal: Curr Protoc Mol Biol Date: 2001-05

Review 3. The complete genomic sequence of the modified vaccinia Ankara strain: comparison with other orthopoxviruses.

Authors: G Antoine; F Scheiflinger; F Dorner; F G Falkner
Journal: Virology Date: 1998-05-10 Impact factor: 3.616

4. Host range and cytopathogenicity of the highly attenuated MVA strain of vaccinia virus: propagation and generation of recombinant viruses in a nonhuman mammalian cell line.

Authors: M W Carroll; B Moss
Journal: Virology Date: 1997-11-24 Impact factor: 3.616

5. Nonreplicating vaccinia vector efficiently expresses recombinant genes.

Authors: G Sutter; B Moss
Journal: Proc Natl Acad Sci U S A Date: 1992-11-15 Impact factor: 11.205

5 in total

16 in total

1. Viral Replicative Capacity, Antigen Availability via Hematogenous Spread, and High T_FH:T_FR Ratios Drive Induction of Potent Neutralizing Antibody Responses.

Authors: Preethi Eldi; Geeta Chaudhri; Stephen L Nutt; Timothy P Newsome; Gunasegaran Karupiah
Journal: J Virol Date: 2019-03-05 Impact factor: 5.103

2. A homolog of the variola virus B22 membrane protein contributes to ectromelia virus pathogenicity in the mouse footpad model.

Authors: Sara E Reynolds; Patricia L Earl; Mahnaz Minai; Ian Moore; Bernard Moss
Journal: Virology Date: 2016-11-26 Impact factor: 3.616

3. Insufficient Innate Immunity Contributes to the Susceptibility of the Castaneous Mouse to Orthopoxvirus Infection.

Authors: Patricia L Earl; Jeffrey L Americo; Bernard Moss
Journal: J Virol Date: 2017-09-12 Impact factor: 5.103

4. Arbovirus Infections As Screening Tools for the Identification of Viral Immunomodulators and Host Antiviral Factors.

Authors: Emily A Rex; Dahee Seo; Don B Gammon
Journal: J Vis Exp Date: 2018-09-13 Impact factor: 1.355

5. A simultaneous oral and intramuscular prime/sublingual boost with a DNA/Modified Vaccinia Ankara viral vector-based vaccine induces simian immunodeficiency virus-specific systemic and mucosal immune responses in juvenile rhesus macaques.

Authors: Alan D Curtis; Kara Jensen; Koen K A Van Rompay; Rama R Amara; Pamela A Kozlowski; Kristina De Paris
Journal: J Med Primatol Date: 2018-09-11 Impact factor: 0.667

6. Constitutively elevated levels of SOCS1 suppress innate responses in DF-1 immortalised chicken fibroblast cells.

Authors: E S Giotis; C S Ross; R C Robey; A Nohturfft; S Goodbourn; M A Skinner
Journal: Sci Rep Date: 2017-12-13 Impact factor: 4.379

7. Novel Nonreplicating Vaccinia Virus Vector Enhances Expression of Heterologous Genes and Suppresses Synthesis of Endogenous Viral Proteins.

Authors: Linda S Wyatt; Wei Xiao; Jeffrey L Americo; Patricia L Earl; Bernard Moss
Journal: mBio Date: 2017-06-06 Impact factor: 7.867

8. Collateral Lethal Effects of Complementary Oncolytic Viruses.

Authors: Justin W Maroun; Velia Penza; Taylor M Weiskittel; Autumn J Schulze; Stephen J Russell
Journal: Mol Ther Oncolytics Date: 2020-06-24 Impact factor: 7.200

9. Generation of a Novel Oncolytic Vaccinia Virus Using the IHD-W Strain.

Authors: Jaeil Shin; Soon-Oh Hong; Minju Kim; Hyesun Lee; Hwanjun Choi; Joonsung Kim; Jieun Hong; Hyesoo Kang; Eunjin Lee; Soondong Lee; Byoungjae Kong; Minjung Kim; Heonsik Choi; Sujeong Kim
Journal: Hum Gene Ther Date: 2020-10-15 Impact factor: 5.695

10. Natural killer cells expanded in vivo or ex vivo with IL-15 overcomes the inherent susceptibility of CAST mice to lethal infection with orthopoxviruses.

Authors: Patricia L Earl; Jeffrey L Americo; Bernard Moss
Journal: PLoS Pathog Date: 2020-04-22 Impact factor: 7.464